help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MYOU, S.
Right arrow Articles by MATSUDA, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MYOU, S.
Right arrow Articles by MATSUDA, T.

Am. J. Respir. Crit. Care Med., Volume 160, Number 3, September 1999, 817-820

Bronchodilator Effect of Inhaled Olprinone, a Phosphodiesterase 3 Inhibitor, in Asthmatic Patients

SHIGEHARU MYOU, MASAKI FUJIMURA, YUMIE KAMIO, YOSHIHISA ISHIURA, HIDEKI TACHIBANA, TATSUKI HIROSE, TAKUMA HASHIMOTO, and TAMOTSU MATSUDA

Third Department of Internal Medicine and Laboratory of Medicine, Kanazawa University School of Medicine, Kanazawa, Japan; and Central Laboratory, Kanazawa University Hospital, Kanazawa, Japan

The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the usefulness of inhaled PDE3 inhibitors in the treatment of asthma, we investigated the bronchodilator effect of inhaled olprinone, a newly developed PDE3 inhibitor, in nine asthmatic patients. On three separate study days, olprinone, salbutamol, or vehicle was administered in a double-blind and randomized fashion, and pulmonary functions were assessed over 60 min. Significant increases in FEV1 were observed until 45 min after inhalation of olprinone without adverse cardiovascular effects. Mean maximal increases in FEV1 were 16.0 ± 4.0 and 20.5 ± 4.2% with olprinone and salbutamol, respectively. The bronchodilator effect of olprinone was greater than that of salbutamol in four of the nine patients. These results suggest that the inhaled PDE3 inhibitor has a bronchodilator effect in asthmatic patients.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
V. Boswell-Smith, D. Spina, A. W. Oxford, M. B. Comer, E. A. Seeds, and C. P. Page
The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 840 - 848.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. A. Giembycz
Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
M. Miyabe, K. Tajima, H. Takahashi, and H. Toyooka
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits: [L'olprinone, un inhibiteur de la phosphodiesterase III, n'a pas d'effet sur la dilatation arteriolaire pie-merienne chez les lapins]
Can J Anesth, February 1, 2003; 50(2): 193 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. Uemura, Y. Fujii, and H. Toyooka
Inhaled olprinone improves contractility of fatigued canine diaphragm
Br. J. Anaesth., March 1, 2002; 88(3): 408 - 411.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society